Home > Insider Trading > Filing (0001127602-16-042274)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
882095	Gilead Sciences Inc	GILD	Biological Products, (No Disgnostic Substances) (2836)	943047598

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1327145	L Robin Washington	Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404	Evp, Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-02-15	248	$76.02	27,972	No	5	A	Direct
Common Stock	Acquisiton	2016-02-16	13,146	$0.00	41,118	No	4	A	Direct
Common Stock	Acquisiton	2016-02-16	35,174	$0.00	76,292	No	4	A	Direct
Common Stock	Disposition	2016-02-16	26,808	$91.15	49,484	No	4	F	Direct
Common Stock	Disposition	2016-02-16	6,250	$90.72	84,688	No	4	S	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	F	Direct
No	4	S	Indirect	By Trust

Footnotes

Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
Represents shares of the Issuer's common stock subject to specific tranches of performance share awards made to the Reporting Person on February 1, 2014, and February 1, 2015. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2016, and committee certifications respectively.
Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2013. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
The transaction reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.